Biotech News
Related news
REPLReplimune Group2026-08-19 20:01 EST
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERNGeron2026-08-18 20:01 EST
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURAKura Oncology2026-08-07 11:30 EST
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDYAIDEAYA Biosciences2026-07-31 10:00 EST
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
FATEFate Therapeutics2026-08-03 20:05 EST
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GERNGeron2026-07-14 20:26 EST
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Merus
Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development. Its platform is built around engineered immunology and cancer programs.
Recent company news
MRUSMerus2025-12-12 07:54 EST
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
MRUSMerus2025-11-17 12:15 EST
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
MRUSMerus2025-10-24 14:00 EST
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
MRUSMerus2025-10-14 11:30 EST
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MRUSMerus2025-10-13 16:00 EST
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States